Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Carcinoma, Renal Cell 2 Triple Negative Breast Neoplasms 1 Refractory/Relapse Neuroblastoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Ovarian Neoplasms 1 Neuroendocrine Tumors 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma, B-Cell 1 Lymphoma 1 Lung Neoplasms 1 Leukemia, B-Cell 1 Kidney Neoplasms 1 Hodgkin Disease 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

Everolimus 10 lutetium Lu 177 dotatate 5 Magnetic Resonance Spectroscopy 5 pasireotide 4 Specimen Handling 3 Positron Emission Tomography Computed Tomography 3 Fluorodeoxyglucose F18 3 (177)Lu-DOTA-EB-TATE 3 olaparib 2 amino-acid, glucose, and electrolyte solution 2 Temozolomide 2 Nivolumab 2 FAPI-46 2 veliparib 1 vandetanib 1 trifluridine tipiracil drug combination 1 toripalimab 1 tislelizumab 1 talazoparib 1 surufatinib 1 romidepsin 1 peposertib 1 pembrolizumab 1 pelcitoclax 1 pegfilgrastim 1 fosbretabulin 1 fludarabine phosphate 1 exemestane 1 decitabine and cedazuridine drug combination 1 dactolisib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Neuroendocrine Tumors × Biological Products × Clear all

NCT07366658 2026-01-26

NEUK203-13

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 1 Not yet recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡